医学
多导睡眠图
持续气道正压
血压
交叉研究
恶化
高海拔对人类的影响
高原病
高度(三角形)
麻醉
慢性阻塞性肺病
内科学
呼吸暂停
物理疗法
心脏病学
阻塞性睡眠呼吸暂停
安慰剂
病理
替代医学
数学
几何学
解剖
作者
Yvonne Nussbaumer‐Ochsner,Nicole Schuepfer,Silvia Ulrich,Konrad E. Bloch
出处
期刊:Thorax
[BMJ]
日期:2010-04-30
卷期号:65 (5): 429-435
被引量:91
标识
DOI:10.1136/thx.2009.125849
摘要
BACKGROUND Many patients with the obstructive sleep apnoea syndrome (OSA) travel to the mountains for recreational and professional activities while temporarily discontinuing continuous positive airway pressure (CPAP) treatment. A study was undertaken to evaluate the hypothesis that altitude would aggravate their hypoxaemia, sleep-related breathing disturbances and impair daytime performance. METHODS Thirty-four patients with OSA of median age 62 years (IQR 57-65), median apnoea/hypopnoea index (AHI) 47.5 events/h (IQR 32.4-72.8), residing at <600 m were enrolled. A crossover trial randomised for the sequence of altitude exposure was carried out: patients spent 1 day in Zurich (490 m) and 4 days in the Swiss Alps at 1860 m and 2590 m (2 days each) during which continuous positive airway pressure was discontinued. Daily evaluations included polysomnography, symptom questionnaires, physical examination and driving simulator tests. RESULTS Polysomnography revealed median oxygen saturations at 490 m and in the first and second nights at 1860 and 2590 m, respectively, of 94%, 90%, 90%, 86% and 87% (p<0.01 between altitudes). Corresponding median AHI were 47.5, 85.1, 74.6, 90.0 and 90.9 events/h (p<0.01 between altitudes) with ratios of central to obstructive events of 0.1, 0.8, 1.0, 1.9 and 1.9 (p<0.01 between altitudes). Tracking performance during simulated driving was significantly impaired at 2590 m compared with 490 m. Systolic blood pressure and cardiac arrhythmias were increased at altitude. CONCLUSIONS Altitude exposure in untreated patients with OSA aggravates hypoxaemia, increases sleep-related breathing disturbances due to frequent central apnoeas/hypopnoeas, impairs driving simulator performance and induces cardiovascular stress. These findings have implications for counselling and treating patients with OSA planning to travel to high altitude. ClinicalTrials.gov identifier NCT00514826.
科研通智能强力驱动
Strongly Powered by AbleSci AI